## P01-222

## PREDICTION OF RESPONSE TO BUPROPION TREATMENT - THE EARLY CHANGE OF PREFRONTAL QEEG CORDANCE. OPEN LABEL STUDY

M. Bares<sup>1,2</sup>, M. Brunovsky<sup>1,2</sup>, T. Novak<sup>1,2</sup>, M. Kopecek<sup>1,2,3</sup>, P. Stopkova<sup>1,2</sup>, P. Sos<sup>1,2</sup>, C. Höschl<sup>1,2</sup>

<sup>1</sup>Prague Psychiatric Centre, <sup>2</sup>The Department of Psychiatry and Medical Psychology, 3rd Faculty of Medicine, Charles University, Prague, Czech Republic, <sup>3</sup>Center for Excellence for Research & Treatment Bipolar Disorder, Department of Psychiatry, University of North Carolina at Chapel Hill, Chapell Hill, USA

**Aims:** Previous studies demonstrated predictive effect of reduction of prefrontal cordance for non-resistant outpatients or resistant inpatients treated by various antidepressants or venlafaxine. The aim of the present study was to examine whether the reduction of theta prefrontal QEEG cordance value after 1 week of bupropion administration is associated with response to 4 weeks treatment in patients with resistant depressive disorder. We extended our previous pilot data.

**Methods:** We analyzed 18 inpatients, who finished 4-week treatment with venlafaxine. EEG data were monitored at baseline and after 1 week of treatment. QEEG cordance was computed at 3 frontal electrodes in theta frequency band. Depressive symptoms were assessed using Montgomery-Åsberg Depression Rating Scale (MADRS).

Results: Nine of 11 responders (reduction of MADRS ≥50%) and no one of 7 non-responders decreased prefrontal QEEG cordance value after the first week of treatment. Positive and negative predictive value (PPV, NPV) of cordance reduction for response to treatment was 1.0 (95% CI, 0.8-1.0) and 0.78 (95% CI, 0.57-0.78), respectively.

**Conclusions:** Based on our results, the prefrontal QEEG cordance might be helpful in the prediction of the response to bupropion treatment in resistant patients.

This study was supported by a grant from Internal Grant Agency of Ministry of Health of Czech Republic No. NR/9330-3 and a grant from Ministry of Health of Czech Republic MZ0PCP2005.